Inhibikase Therapeutics, Inc.(IKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IKT Inhibikase Therapeutics, Inc.

Pre-Mkt 12-18 09:25:02 EST

1.59

-0.01

-0.62%

盘前1.66

+0.07+4.45%

08:00 EST

High1.64	Low1.55	Vol609.25K
Open1.59	D1 Closing1.60	Amplitude5.63%
Mkt Cap192.39M	Tradable Cap113.06M	Total Shares121.00M
T/O965.93K	T/O Rate0.86%	Tradable Shares71.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IKT","market":"US","secType":"STK","nameCN":"Inhibikase Therapeutics, Inc.","latestPrice":1.59,"timestamp":1766005200000,"preClose":1.6,"halted":0,"volume":609250,"hourTrading":{"tag":"盘前","latestPrice":1.6607,"preClose":1.59,"latestTime":"08:00 EST","volume":50,"amount":83.035,"timestamp":1766062805004},"delay":0,"floatShares":71105000,"shares":121000000,"eps":-0.557921,"marketStatus":"Pre-Mkt","change":-0.01,"latestTime":"12-18 09:25:02 EST","open":1.59,"high":1.64,"low":1.55,"amount":965932.815393,"amplitude":0.05625,"askPrice":1.65,"askSize":1,"bidPrice":1.5,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.557921,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766068200000},"marketStatusCode":1,"adr":0,"listingDate":1608699600000,"exchange":"NASDAQ","adjPreClose":1.59,"preHourTrading":{"tag":"盘前","latestPrice":1.6607,"preClose":1.59,"latestTime":"08:00 EST","volume":50,"amount":83.035,"timestamp":1766062805004},"postHourTrading":{"tag":"盘后","latestPrice":1.59,"preClose":1.59,"latestTime":"16:10 EST","volume":2277,"amount":3620.43,"timestamp":1766005804765},"volumeRatio":0.9454862939772907},"requestUrl":"/m/hq/s/IKT/tweets","defaultTab":"tweets","newsList":[{"id":"2591762390","title":"Indonesia Launches First 48-Ton Frozen Durian Export to China","url":"https://stock-news.laohu8.com/highlight/detail?id=2591762390","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591762390?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:35","pubTimestamp":1765798548,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta - Indonesia has secured its first direct export of frozen durian to China, marking a major milestone after nearly two years of negotiations and regulatory preparations.The inaugural ","market":"other","thumbnail":"https://statik.tempo.co/data/2025/12/15/id_1447704/1447704_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/12/15/id_1447704/1447704_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2073612/indonesia-launches-first-48-ton-frozen-durian-export-to-china","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2073612/indonesia-launches-first-48-ton-frozen-durian-export-to-china","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2590467512","title":"Inhibikase Therapeutics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2590467512","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590467512?lang=en_us&edition=fundamental","pubTime":"2025-12-11 23:07","pubTimestamp":1765465620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IKT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2025 10:07 ET (15:07 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT"],"gpt_icon":0},{"id":"2590515664","title":"Cantor Fitzgerald Initiates Inhibikase Therapeutics With Overweight Rating, $4 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515664","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590515664?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:44","pubTimestamp":1765457056,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics (IKT) has an average rating of Buy and mean price target of $6.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IKT"],"gpt_icon":0},{"id":"2586443743","title":"Inhibikase Therapeutics Reports Q3 2025 Financials and Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2586443743","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586443743?lang=en_us&edition=fundamental","pubTime":"2025-11-25 11:52","pubTimestamp":1764042742,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics, Inc. ( ($IKT) ) has released its Q3 earnings. Here is a breakdown of the information Inhibikase Therapeutics, Inc. present...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inhibikase-therapeutics-reports-q3-2025-financials-and-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inhibikase-therapeutics-reports-q3-2025-financials-and-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PRGS","LU2065732104.USD","BK4097","IKT"],"gpt_icon":0},{"id":"2586497163","title":"Sands Capital Life Sciences Pulse Fund II Reports Acquisition of Inhibikase Therapeutics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586497163","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586497163?lang=en_us&edition=fundamental","pubTime":"2025-11-25 04:47","pubTimestamp":1764017263,"startTime":"0","endTime":"0","summary":"Sands Capital Life Sciences Pulse Fund II, L.P. has reported the acquisition of common shares of Inhibikase Therapeutics Inc. , according to a recent regulatory filing. The filing was submitted by Sands Capital Life Sciences Pulse Fund II, L.P. along with other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL2swsVt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Sands Capital Life Sciences Pulse Fund II Reports Acquisition of Inhibikase Therapeutics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2585293001","title":"Inhibikase Therapeutics Announces $93.6 Million Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2585293001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585293001?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:48","pubTimestamp":1763761730,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics ( ($IKT) ) has provided an announcement. On November 20, 2025, Inhibikase Therapeutics, Inc. announced an underwriting agre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inhibikase-therapeutics-announces-93-6-million-stock-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inhibikase-therapeutics-announces-93-6-million-stock-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2585811141","title":"Inhibikase Therapeutics Shares up 7.2% Premarket After Co Advances Experimental Pulmonary Arterial Hypertension Drug to Late-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2585811141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585811141?lang=en_us&edition=fundamental","pubTime":"2025-11-21 18:25","pubTimestamp":1763720747,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nL4N3WX0QO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2585619512","title":"Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2585619512","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585619512?lang=en_us&edition=fundamental","pubTime":"2025-11-21 12:00","pubTimestamp":1763697611,"startTime":"0","endTime":"0","summary":"The deal priced below last closing price of $1.53. Jefferies, BofA and Cantor Fitzgerald are acting as joint book running managers for the offering...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inhibikase-therapeutics-46-1m-share-spot-secondary-priced-at-1-45-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inhibikase-therapeutics-46-1m-share-spot-secondary-priced-at-1-45-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IKT"],"gpt_icon":0},{"id":"2585919838","title":"BRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2585919838","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585919838?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:57","pubTimestamp":1763693837,"startTime":"0","endTime":"0","summary":"BRIEF-Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per ShareNov 20 (Reuters) - Inhibikase Therapeutics Inc IKT.O:INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF $100 MILLI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUARRFB5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2585855198","title":"Inhibikase Therapeutics Inc - Prices Public Offering of 46 Mln Shares at $1.45 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2585855198","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585855198?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:54","pubTimestamp":1763693686,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nTUARRFB5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IKT"],"gpt_icon":0},{"id":"2585716889","title":"Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2585716889","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585716889?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:29","pubTimestamp":1763674158,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics ( ($IKT) ) has provided an announcement. On November 20, 2025, Inhibikase Therapeutics announced plans to advance IKT-001 t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inhibikase-therapeutics-advances-ikt-001-to-phase-3-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inhibikase-therapeutics-advances-ikt-001-to-phase-3-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IKT"],"gpt_icon":0},{"id":"2585685831","title":"Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2585685831","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585685831?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:12","pubTimestamp":1763673120,"startTime":"0","endTime":"0","summary":"BOSTON and ATLANTA, Nov.  20, 2025  (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (NASDAQ: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3192391/0/en/Inhibikase-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IKT"],"gpt_icon":0},{"id":"2585506031","title":"Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH","url":"https://stock-news.laohu8.com/highlight/detail?id=2585506031","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585506031?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:11","pubTimestamp":1763673111,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics (IKT) announced that it expects to advance IKT-001 to a global pivotal Phase 3 clinical study in Pulmonary Arterial Hyperte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inhibikase-therapeutics-to-advance-ikt-001-to-phase-3-clinical-study-in-pah-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inhibikase-therapeutics-to-advance-ikt-001-to-phase-3-clinical-study-in-pah-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2585574541","title":"Inhibikase Therapeutics Inc - Improve-Pah Phase 3 Study Expected to Start in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2585574541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585574541?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:01","pubTimestamp":1763672482,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW1JQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IKT"],"gpt_icon":0},{"id":"2585168340","title":"Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168340","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168340?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:01","pubTimestamp":1763672460,"startTime":"0","endTime":"0","summary":"Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years  BOSTON and ATLANTA, Nov.  20, 2025  (GLOBE NEWSWIRE) -- Inh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3192370/0/en/Inhibikase-Therapeutics-Advancing-IKT-001-to-Global-Phase-3-Study-in-Pulmonary-Arterial-Hypertension.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IKT"],"gpt_icon":0},{"id":"2584954190","title":"Inhibikase Therapeutics: Strategic Advancements and Financial Strength Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2584954190","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584954190?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:45","pubTimestamp":1763484334,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inhibikase Therapeutics, with a price target of $8.00. J...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/inhibikase-therapeutics-strategic-advancements-and-financial-strength-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/inhibikase-therapeutics-strategic-advancements-and-financial-strength-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IKT"],"gpt_icon":0},{"id":"2583681041","title":"Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681041","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681041?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:09","pubTimestamp":1763154597,"startTime":"0","endTime":"0","summary":"Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widensOverviewInhibikase Q3 net loss widens to $11.9 mln, driven by increased R&D and SG&A expensesCash reserves drop to $77.3 mln from $","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nL1N3WQ13H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2583812336","title":"Inhibikase Therapeutics Q3 EPS $(0.13), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2583812336","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583812336?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:03","pubTimestamp":1763154181,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 80 percent increase over losses of $(0.65) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48879529/inhibikase-therapeutics-q3-eps-0-13-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Inhibikase Therapeutics Q3 EPS $(0.13), Inline","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT"],"gpt_icon":0},{"id":"2583681474","title":"Press Release: Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681474","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681474?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:01","pubTimestamp":1763154060,"startTime":"0","endTime":"0","summary":"BOSTON and ATLANTA, Nov. 14, 2025  -- Inhibikase Therapeutics, Inc.  , a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension , today reported financial results for the quarter ended September 30, 2025 and highlighted recent developments.\"During our third quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,\" said Mark Iwicki, Chief Executive Officer of Inhibikase. \"We expect to initiate our Phase 2b clinical study of IKT-001, our prodrug of imatinib mesylate, in PAH during the fourth quarter of 2025.\". -- The proposed Phase 2b IMPROVE-PAH trial is a multi-center,will be randomized 1:1:1 to receive 300 mg IKT-001, 500 mg. IKT-001, or placebo once daily for 26 weeks, in addition to stable. previously confirmed that 500 mg of IKT-001 has comparable. exposure in humans to 383 mg of imatinib. The primary efficacy. endpoint is change","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"gpt_icon":0},{"id":"2560196945","title":"Inhibikase Therapeutics Appoints Timothy Pigot as Chief Commercial and Strategy Officer to Bolster Leadership Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2560196945","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560196945?lang=en_us&edition=fundamental","pubTime":"2025-08-19 20:00","pubTimestamp":1755604826,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics Inc., a clinical-stage pharmaceutical company focused on pulmonary arterial hypertension , has appointed Timothy Pigot as Chief Commercial and Strategy Officer. Pigot brings over 30 years of experience in the pharmaceutical industry, having previously served as Chief Commercial Officer at Aerovate Therapeutics and Vice President of Marketing at MyoKardia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on August 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDLjRcXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE0009355771.USD","BK4559","LU1430594728.SGD","LU0868494617.USD","LU2210149790.SGD","LU0321505439.SGD","LU1571399168.USD","LU1670710661.SGD","BK4139","LU0114720955.EUR","LU1093756168.USD","LU1074936037.SGD","NDAQ","LU1868837136.USD","LU1670711040.USD","LU2242652126.USD","LU1323610961.USD","IE00BFXG1179.USD","IKT","BK4112","LU0314104364.USD","LU0306807586.USD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0096364046.USD","LU1670711123.USD","LU1718418525.SGD","LU1670710588.SGD","LU1868837300.USD","IE00BKPKM429.USD","LU1868836914.USD","IE0002141913.USD","LU2360032135.SGD","BK4007","LU0882574055.USD","LU1585245621.USD","LU2133065610.SGD","LU0306806265.USD","LU1868836591.USD","LU1261432733.SGD","LU0225284248.USD","LU1989771016.USD","BK4532","BMY","IE00B64PRP62.GBP","LU1291159041.SGD","IE00B2B36J28.USD","LU1032466523.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inhibikase.com","stockEarnings":[{"period":"1week","weight":0.0743},{"period":"1month","weight":0.0461},{"period":"3month","weight":0.0325},{"period":"6month","weight":-0.0422},{"period":"1year","weight":-0.5995},{"period":"ytd","weight":-0.5108}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.280454},{"month":2,"riseRate":0.6,"avgChangeRate":-0.092117},{"month":3,"riseRate":0.2,"avgChangeRate":0.027077},{"month":4,"riseRate":0.2,"avgChangeRate":-0.167556},{"month":5,"riseRate":0.6,"avgChangeRate":0.04864},{"month":6,"riseRate":0,"avgChangeRate":-0.232697},{"month":7,"riseRate":0.4,"avgChangeRate":-0.074238},{"month":8,"riseRate":0.6,"avgChangeRate":0.020579},{"month":9,"riseRate":0,"avgChangeRate":-0.145977},{"month":10,"riseRate":0.4,"avgChangeRate":0.077339},{"month":11,"riseRate":0.8,"avgChangeRate":0.007082},{"month":12,"riseRate":0.6,"avgChangeRate":0.014981}],"exchange":"NASDAQ","name":"Inhibikase Therapeutics, Inc.","nameEN":"Inhibikase Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inhibikase Therapeutics, Inc.(IKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inhibikase Therapeutics, Inc.(IKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inhibikase Therapeutics, Inc.,IKT,Inhibikase Therapeutics, Inc.股票,Inhibikase Therapeutics, Inc.股票老虎,Inhibikase Therapeutics, Inc.股票老虎国际,Inhibikase Therapeutics, Inc.行情,Inhibikase Therapeutics, Inc.股票行情,Inhibikase Therapeutics, Inc.股价,Inhibikase Therapeutics, Inc.股市,Inhibikase Therapeutics, Inc.股票价格,Inhibikase Therapeutics, Inc.股票交易,Inhibikase Therapeutics, Inc.股票购买,Inhibikase Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inhibikase Therapeutics, Inc.(IKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inhibikase Therapeutics, Inc.(IKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction